Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | G667fs |
Impact List | frameshift |
Protein Effect | unknown |
Gene Variant Descriptions | FBXW7 G667fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 667 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). G667fs has been identified in the scientific literature (PMID: 25562415), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Oct 2024). |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 G667fs |
Transcript | NM_033632.3 |
gDNA | chr4:g.(152323006_152323007) |
cDNA | c.(1999_1998) |
Protein | p.G667fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024454122.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
NM_033632 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.(152323006_152323007) | c.(1999_1998) | p.G667fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 mutant | Her2-receptor negative breast cancer | predicted - sensitive | LY3039478 | Case Reports/Case Series | Actionable | In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005). | 30060061 |